These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1266811)

  • 1. Unusual intravascular material in the brain. Autopsy findings in a patient treated with antihemophilic factor concentrates.
    Ghatak NR; Husain MH
    Am J Clin Pathol; 1976 Apr; 65(4):508-12. PubMed ID: 1266811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
    Bennett B; Ratnoff OD
    J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of hemophilia A with a new antihemophilic fraction "AHF SRK (human)". Comparison with the antihemophilic globulin AHG SRK].
    Duckert F; Müller G; Meili EO
    Schweiz Med Wochenschr; 1971 Dec; 101(50):1831-8. PubMed ID: 5173501
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates.
    Boese EC; Tantum KR; Eyster ME
    Am J Med; 1979 Sep; 67(3):474-6. PubMed ID: 474593
    [No Abstract]   [Full Text] [Related]  

  • 5. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cryoprecipitation and dextran precipitation in obtaining factor VIII concentrates: results of redetecting antihemophilic globulin A in a patient].
    Kubel M; Wegner H; Liebe S
    Z Gesamte Inn Med; 1974 Mar; 29(6):236-40. PubMed ID: 4409090
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemolysis caused by factor VIII concentrates.
    Orringer EP; Koury MJ; Blatt PM; Roberts HR
    Arch Intern Med; 1976 Sep; 136(9):1018-20. PubMed ID: 962445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostatectomy in an 85-year-old hemophiliac.
    Wylin R; Schneider J
    Arch Surg; 1976 Jul; 111(7):818-21. PubMed ID: 59587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hemophilia A with actor VIII concentrate in urological operations and injuries of the urinary tract].
    Brühl P; Weibbach L; Brackmann HH
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):401-4. PubMed ID: 804604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation products and their uses.
    Shord SS; Lindley CM
    Am J Health Syst Pharm; 2000 Aug; 57(15):1403-17; quiz 1418-20. PubMed ID: 10938981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspects of the management of hemophilia in childhood. Availability of newer concentrates of antihemophilic factor failitates management.
    Strauss HS
    R I Med J; 1966 Aug; 49(8):466-8. PubMed ID: 5222119
    [No Abstract]   [Full Text] [Related]  

  • 12. [A contribution to the intravascular coagulation in cerebral malaria (author's transl)].
    Meyer-Breiting E; Zimmermann H
    Zentralbl Allg Pathol; 1975; 119(4):286-93. PubMed ID: 1189680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors.
    Brinkhous KM; Shanbrom E; Roberts HR; Webster WP; Fekete L; Wagner RH
    JAMA; 1968 Aug; 205(9):613-7. PubMed ID: 5695099
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional antihemophilic factor to be available.
    Thompson CA
    Am J Health Syst Pharm; 2008 Apr; 65(7):592. PubMed ID: 18359961
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII concentrates made in the United Kingdom and the treatment of haemophilia based on studies made during 1969--72. Report of the Medical Research Council's Blood Transfusion Research Committee Working Party on the cryoprecipitate method of preparing AHF concentrates.
    Br J Haematol; 1974 Jul; 27(3):391-405. PubMed ID: 4413414
    [No Abstract]   [Full Text] [Related]  

  • 17. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.
    Blatt PM; Brinkhous KM; Culp HR; Krauss JS; Roberts HR
    JAMA; 1976 Dec; 236(24):2770-2. PubMed ID: 1086910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of psychiatric intervention on use of antihemophilic factor concentrate.
    Handford AH; Charney D; Ackerman L; Eyster ME; Bixler EO
    Am J Psychiatry; 1980 Oct; 137(10):1254-6. PubMed ID: 6774621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.